Pricing Log in Create free account
Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

20.24 0.79 +4.06%
Market cap
$6.8B
P/E
36.9×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. 8-K filed Jan 15, 2025

Period ended Jan 15, 2025 · Filed · accepted 6:14 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov